Top

Published in:

01-08-2012 | Original Article

Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis

Authors: Ki-Jo Kim, Ji-Young Kim, Su-Jung Park, Hosung Yoon, Chong-Hyeon Yoon, Wan-Uk Kim, Chul-Soo Cho

Published in: Clinical Rheumatology | Issue 8/2012

Abstract

The aim of this study is to clarify the association between serum leptin levels and the presence of syndesmophytes in male patients with ankylosing spondylitis (AS). Seventy-two male patients with AS and 20 age-matched healthy male controls were included. Patients were stratified by the presence of syndesmophytes. Serum leptin levels were measured and adjusted for body mass index (BMI). In addition, bone-specific alkaline phosphatase (BALP), osteocalcin, and telopeptide of type I collagen were determined. Patients with syndesmophytes were associated with older age (p < 0.001), longer disease duration (p = 0.003), and higher BMI (p = 0.038). Serum leptin levels and leptin per BMI (leptin/BMI) ratio were not different between AS patients and healthy controls. However, serum leptin/BMI ratio was significantly higher in patients with syndesmophytes compared to those without (p = 0.010). In multivariate analysis, higher serum leptin/BMI ratio remained significantly associated with the presence of syndesmophytes (p = 0.029). Moreover, serum leptin/BMI ratio was positively correlated with serum BALP (γ = 0.279, p = 0.039). However, there was no significant association between serum leptin/BMI ratio and bone mineral density. Serum leptin levels are elevated in male AS patients with syndesmophytes and were found to be correlated with bone formation marker, suggesting a potential role of leptin in new bone formation in AS.

Maksymowych WP (2010) Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 6(2):75–81PubMedCrossRef

El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71(4):291–295PubMedCrossRef

Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53(2):117–121PubMedCrossRef

Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298PubMed

Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2(1):35–43PubMedCrossRef

Kawai M, Devlin MJ, Rosen CJ (2009) Fat targets for skeletal health. Nat Rev Rheumatol 5(7):365–372PubMedCrossRef

Shi Y, Yadav VK, Suda N, Liu XS, Guo XE et al (2008) Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci USA 105(51):20529–20533PubMedCrossRef

Scheller EL, Song J, Dishowitz MI, Soki FN, Hankenson KD et al (2010) Leptin functions peripherally to regulate differentiation of mesenchymal progenitor cells. Stem Cells 28(6):1071–1080PubMedCrossRef

Gordeladze JO, Drevon CA, Syversen U, Reseland JE (2002) Leptin stimulates human osteobltic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteocltic signaling. J Cell Biochem 85(4):825–836PubMedCrossRef

10.

Reseland JE, Gordeladze JO (2002) Role of leptin in bone growth: central player or peripheral supporter? FEBS Lett 528(1–3):40–42PubMedCrossRef

11.

Thomas T, Burguera B (2002) Is leptin the link between fat and bone mass? J Bone Miner Res 17(9):1563–1569PubMedCrossRef

12.

Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E et al (1997) The metabolic significance of leptin in humans: gender-bed differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 82(4):1293–1300PubMedCrossRef

13.

van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef

14.

Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S et al (2004) What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods bed on the Outcome Meures in Rheumatology Clinical Trials filter. Arthritis Rheum 50(8):2622–2632PubMedCrossRef

15.

World Health Organization (1994) sessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

16.

Chen K, Li F, Li J, Cai H, Strom S et al (2006) Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 12(4):425–432PubMedCrossRef

17.

Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disee activity in patients with ankylosing spondylitis. Scand J Rheumatol 36(2):101–106PubMedCrossRef

18.

Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 100(11):2777–2782PubMedCrossRef

19.

Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegler R et al (1997) Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 82(12):4080–4082PubMedCrossRef

20.

Gilgil E, Kacar C, Tuncer T, Butun B (2005) The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol 32(2):292–294PubMed

21.

Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huede G et al (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56(10):1383–1389PubMedCrossRef

22.

Park MC, Chung SJ, Park YB, Lee SK (2009) Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine 76(2):170–175PubMedCrossRef

23.

Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA et al (2010) Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol 28(6):880–883PubMed

24.

Lilja M, Rolandsson O, Shaw JE, Pauvaday V, Cameron AJ et al (2010) Higher leptin levels in Asian Indians than Creoles and Europids: a potential explanation for increased metabolic risk. Int J Obes (Lond) 34(5):878–885CrossRef

25.

van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H et al (2011) Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 71:518–23PubMedCrossRef

26.

Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M et al (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60(1):93–102PubMedCrossRef

27.

Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N et al (2004) Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101(9):3258–3263PubMedCrossRef

28.

Ducy P, Amling M, Takeda S, Priemel M, Schilling AF et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone ms. Cell 100(2):197–207PubMedCrossRef

29.

Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG (2000) Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92(1–3):73–78PubMedCrossRef

30.

Martin A, David V, Malaval L, Lafage-Proust MH, Vico L et al (2007) Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology 148(7):3419–3425PubMedCrossRef

31.

Thomas T, Gori F, Khosla S, Jensen MD, Burguera B et al (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140(4):1630–1638PubMedCrossRef

32.

Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG et al (2001) Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 16(8):1426–1433PubMedCrossRef

33.

Bajoria R, Sooranna SR, Chatterjee R (2007) Leptin and bone turnover in monochorionic twins complicated by twin-twin transfusion syndrome. Osteoporos Int 18(2):193–200PubMedCrossRef

34.

Morberg CM, Tetens I, Black E, Toubro S, Soerensen TI et al (2003) Leptin and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol Metab 88(12):5795–5800PubMedCrossRef

35.

Scariano JK, Garry PJ, Montoya GD, Chandani AK, Wilson JM et al (2003) Serum leptin levels, bone mineral density and osteoblast alkaline phosphatase activity in elderly men and women. Mech Ageing Dev 124(3):281–286PubMedCrossRef

36.

Ikeda Y, Nakajima A, Aiba A, Koda M, Okawa A et al (2011) Association between serum leptin and bone metabolic markers, and the development of heterotopic ossification of the spinal ligament in female patients with ossification of the posterior longitudinal ligament. Eur Spine J 20(9):1450–1458PubMedCrossRef

37.

Kaplan FS, Glaser DL, Hebela N, Shore EM (2004) Heterotopic ossification. J Am Acad Orthop Surg 12(2):116–125PubMed

38.

Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225PubMedCrossRef

39.

Bennett AN, Rehman A, Hensor EM, Marzo-Ortega H, Emery P et al (2010) The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 69(5):891–894PubMedCrossRef

40.

Mutabaruka MS, Aoulad Aissa M, Delalandre A, Lavigne M, Lajeunesse D (2010) Local leptin production in osterthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression. Arthritis Res Ther 12(1):R20PubMedCrossRef

41.

Komaki Y, Sugiura H, Koarai A, Tomaki M, Ogawa H et al (2005) Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm armacol Ther 18(4):297–302CrossRef

42.

Appel H, Maier R, Loddenkemper C, Kayser R, Meier O et al (2010) Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol 37(4):823–828PubMedCrossRef

43.

Dumond H, Presle N, Terlain B, Mainard D, Loeuille D et al (2003) Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 48(11):3118–3129PubMedCrossRef

44.

Donahue RP, Zimmet P, Bean JA, Decourten M, DeCarlo Donahue RA et al (1999) Cigarette smoking, alcohol use, and physical activity in relation to serum leptin levels in a multiethnic population: The Miami Community Health Study. Ann Epidemiol 9(2):108–113PubMedCrossRef

45.

Kelesidis T, Kelesidis I, Chou S, Mantzoros CS (2010) Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152(2):93–100PubMed

Title: Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis
Authors: Ki-Jo Kim
Ji-Young Kim
Su-Jung Park
Hosung Yoon
Chong-Hyeon Yoon
Wan-Uk Kim
Chul-Soo Cho
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 8/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-012-1999-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up

Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

The prevalence of radiographic femoroacetabular impingement in younger individuals undergoing total hip replacement for osteoarthritis

A randomized controlled trial of 8-form Tai chi improves symptoms and functional mobility in fibromyalgia patients

Treatment of frozen shoulder with subcutaneous TNF-alpha blockade compared with local glucocorticoid injection: a randomised pilot study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials